At a glance
- Originator Nippon Shinyaku
- Class Antihyperlipidaemics; Benzoic acids; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 19 Jun 1997 No-Development-Reported for Hyperlipidaemia in Japan (Unknown route)